与胰腺癌相关的激肽释放酶家族：潜在治疗靶点的机制理解
Kallikrein-related peptidases: mechanistic understanding for potential therapeutic targeting in cancer
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:4.4
分区:医学2区 / 药学2区
发表日期:2024 Oct
作者:
Glykeria N Daneva, Panagiotis Tsiakanikas, Panagiotis G Adamopoulos, Andreas Scorilas
DOI:
10.1080/14728222.2024.2415014
摘要
人类激肽释放酶（KLKs）属于15种丝氨酸内肽酶的亚组，参与多种生理过程及病理状态，包括癌症。本综述旨在提供关于KLK家族的全面概述，重点介绍其基因组结构、表达谱及底物特异性。我们探讨KLK在肿瘤发生中的作用，强调其作为癌症生物标志物和治疗靶点的潜力。KLK的异常活性与多种恶性肿瘤相关，使其成为癌症诊断与治疗的有前途的候选分子。近期对KLK相关肿瘤发生机制的深入理解，为开发靶向癌症的治疗策略提供了新前景。专家意见认为，尽管已取得显著进展，但仍需进一步研究以充分发挥KLK在临床中的潜力。
Abstract
Human kallikrein-related peptidases (KLKs) represent a subgroup of 15 serine endopeptidases involved in various physiological processes and pathologies, including cancer.This review aims to provide a comprehensive overview of the KLK family, highlighting their genomic structure, expression profiles and substrate specificity. We explore the role of KLKs in tumorigenesis, emphasizing their potential as biomarkers and therapeutic targets in cancer treatment. The dysregulated activity of KLKs has been linked to various malignancies, making them promising candidates for cancer diagnostics and therapy.: Recent advancements in understanding the mechanistic pathways of KLK-related tumorigenesis offer new prospects for developing targeted cancer treatments. Expert opinion suggests that while significant progress has been made, further research is necessary to fully exploit KLKs' potential in clinical applications.